



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

International Application of:

KAUTZ, et al.

Serial No. 10/524,819 Examiner: AULAKH, C.
Filed: February 18, 2005 Group Art Unit: 1625
Title: 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

☐ a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

☒ b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

☐ i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or

☒ ii. a check in the amount required by 37 C.F.R. 1.17(p).

☐ c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

☐ Certification report(e) below; and

☐ a check in the amount as required by 1.17(p).

☐ d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file. 04/11/2006 HDEYEN1 00000015 10524819

☐ e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.] 02 FC:1886 180.00 OP

☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

[~~XXX~~] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[~~XXX~~] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and/or

[] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.


Respectfully submitted,

NATH & ASSOCIATES PLLC


Date: April 7, 2006
NATH & ASSOCIATES PLLC
112 South West Street
Alexandria, VA 22314

Tel: (703) 548-6284
Fax: (703) 683-8396

JBG/SMM\IDS.doc



Gary M. Nath
Reg. No. 26,965
Joshua B. Goldberg
Reg. No. 44,126
Sheldon M. McGee
Reg. No. 50,454
Customer No. 34375



FORM PTO-1449

Attorney Docket
26588U

Serial Number: 10/524,819

Filing Date: February 18, 2005

INFORMATION DISCLOSURE CITATION

Inventor:
KAUTZ, et al.

Group Art Unit: 1625

U.S. PATENT DOCUMENTS

Exam. Initial	Document Number	Issue Date	Name	Class	Sub- Class	Filing Date
A1						
A2						
A3						
A4						

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub- Class	Translation
A5						
A6						
A7						
A8						
A9						
A10						
A11						
A12						
A13						
A14						
A15						
A16						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

A17	Souness et al., "Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors", <u>Immunopharmacology</u> , Vol. 47 (2000), pp. 127-162.
A18	Montana et al., "Chapter 5. Phosphodiesterase 4 Inhibitors", <u>Annual Reports in Medicinal Chemistry</u> , Vol. 36 (2001), pp. 47-56.
A19	Schmidt et al., "The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis", <u>J. Allergy Clin. Immunol.</u> , Vol. 108, No. 4 (2001), pp. 530-536.
A20	Dyke et al., "Update on the therapeutic potential of PDE4 inhibitors", <u>Expert Opin. Investig. Drugs</u> , Vol. 11, No. 1 (2002), pp. 1-13.
A21	
A22	

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.